Transcriptionally regulated, prostate-targeted gene therapy for prostate cancer

Yi Lu1

  • 1Department of Pathology and Laboratory Medicine, University of Tennessee Health Science Center, Memphis, TN 38163, USA. ylu@utmem.edu

Insights

Transcriptionally regulated gene therapy offers a promising approach to treating prostate cancer by targeting tumor cells specifically. This strategy aims to improve treatment efficacy and reduce side effects associated with earlier gene therapy methods.

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Prostate cancer is a leading cause of cancer death in American men.
  • Current treatments lack specificity, leading to toxicity.
  • Gene therapy presents a novel treatment avenue, but early methods had limitations.

Purpose of the Study:

  • To review transcriptionally regulated gene therapy for prostate cancer.
  • To explore advancements in prostate-targeted viral vector development.
  • To discuss therapeutic strategies, including oncolytic virotherapy.

Main Methods:

  • Comparison of viral delivery routes to the prostate.
  • In vitro and in vivo evaluation of prostate-specific promoters for transgene expression.
  • Selection of therapeutic genes and oncolytic viruses.

Main Results:

  • Development of transcriptionally regulated, prostate-targeted viral vectors.
  • Demonstration of specificity and activity of transgenes in prostate cancer models.
  • Identification of effective therapeutic strategies and transgenes.

Conclusions:

  • Transcriptionally regulated gene therapy shows potential for effective and specific prostate cancer treatment.
  • Further research into viral delivery, promoter selection, and therapeutic agents is ongoing.
  • Challenges and future directions in prostate cancer gene therapy are identified.

Related Concept Videos

Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.7K
Master Transcription Regulators02:23

Master Transcription Regulators

No description available
2.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.7K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome.  Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.2K
Cooperative Binding of Transcription Regulators02:13

Cooperative Binding of Transcription Regulators

No description available
2.5K
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.4K